@article{11037,
  keywords = {Humans, Male, *Muscular Dystrophy, Duchenne/epidemiology/therapy, Retrospective Studies, Longitudinal Studies, Adrenal Cortex Hormones, *Cardiomyopathies/complications, United Kingdom/epidemiology, Duchenne muscular dystrophy, Economic models, Electronic Health Records, statistical models, fees from Duchenne UK. Michela Guglieri has received research funding from, Sarepta, PTC, Muscular Dystrophy UK, NIH and H2020, is (or has been) chief, investigator/principal investigator for clinical trials of Pfizer, Italfarmaco,, Santhera, Roche, ReveraGen, Dynacure, Dyne, is a member of Advisory boards for, Pfizer, NS Pharma, Dyne (honoraria through Newcastle University), and has, received speaker honoraria from Sarepta, Italfarmaco, Novartis and Roche.},
  author = {J. Broomfield and K. Abrams and N. Latimer and M. Guglieri and M. Rutherford and M. Crowther},
  title = {Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink},
  year = {2023},
  journal = {Brain Behav},
  volume = {13},
  edition = {2023/11/14},
  number = {12},
  pages = {e3331},
  doi = {10.1002/brb3.3331},
  note = {2162-3279
Broomfield, Jonathan
Orcid: 0000-0003-1846-2150
Abrams, Keith
Latimer, Nick
Guglieri, Michela
Rutherford, Mark
Crowther, Michael
NIHR300984/National Institute for Health and Care Research/
Journal Article
United States
Brain Behav. 2023 Dec;13(12):e3331. doi: 10.1002/brb3.3331. Epub 2023 Nov 13.},
  language = {eng},
}